David Hammond on How the Red Cross Sifts Through Liters of Plasma | GenomeWeb

At A Glance

Name: David Hammond

Position: Executive director of Plasma Derivatives Department, American Red Cross, Holland Laboratory, since 2000.

Co-founder, Pathogen Removal and Diagnostic Technologies.

Background: Director, Plasma Proteins, V.I.Technologies, 1997-2000.

Director, Biological Research, Bayer, 1996-97.

Director, Technology, Bayer, 1991-96.

Senior scientist/associate director of cell and molecular biology, cancer research, Bristol-Meyers Squibb, 1986-91.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.